1. Home
  2. IMUX vs HELP Comparison

IMUX vs HELP Comparison

Compare IMUX & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.99

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$7.05

Market Cap

233.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMUX
HELP
Founded
2016
N/A
Country
United States
Canada
Employees
66
50
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.2M
233.0M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
IMUX
HELP
Price
$14.99
$7.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$36.00
$51.50
AVG Volume (30 Days)
174.0K
1.5M
Earning Date
05-14-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
38.00
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$3.76
52 Week High
$15.84
$8.55

Technical Indicators

Market Signals
Indicator
IMUX
HELP
Relative Strength Index (RSI) 59.12 69.17
Support Level $0.74 $5.77
Resistance Level $15.81 $8.55
Average True Range (ATR) 0.82 0.48
MACD -0.14 0.06
Stochastic Oscillator 51.75 80.12

Price Performance

Historical Comparison
IMUX
HELP

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: